CQS (US)’s CRISPR Therapeutics CRSP Stock Holding History

CQS (US)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-102,505	Closed	-$6.43M	–	98
2022 Q1	$6.43M	Buy	+102,505	New	+$6.44M	0.44%	69

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

CQS (US)'s CRSP Position: Q2 2022 in Review

CQS (US) sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 102,505 shares — an estimated $6.43M sold.

CQS (US) first reported a position in CRSP in Q1 2022 and held it in 1 quarter. The position peaked at $6.43M in Q1 2022. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

CQS (US) reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
CQS (US) sold 102,505 CRISPR Therapeutics shares in Q2 2022, an estimated $6.43M.
CQS (US) first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 1 quarter.
CQS (US)'s CRISPR Therapeutics position peaked at $6.43M in Q1 2022.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on CQS (US)'s 13F filing for Q2 2022, filed 12 Aug 2022.